Skip to Content

DaxibotulinumtoxinA for Injection (DAXI)*

Potentially the first long-lasting neuromodulator

A new era of neuromodulator science that may unlock the true promise of botulinum toxin type A (BoNT-A)

150kD Botulinum Toxin Type A

Stabilizing Peptide Excipient

Buffers, Sugar and Polysorbate 20

DaxibotulinumtoxinA for Injection

Interest in the benefits of BoNT-A injections has skyrocketed, yet the patient experience has remained largely unchanged.
DAXI redefines the expectations of how a neuromodulator treatment may perform, endure, and deliver.

image description
24 weeks

The median duration of results achieved in clinical trials with DAXI for the treatment of moderate to severe glabellar lines*1

image description
28 Weeks

The median time to return to baseline wrinkle severity in clinical trials with DAXI*1

image description
95%

Response rate for DAXI across the largest aesthetic neuromodulator clinical trial ever conducted dataset. 4,5
*this data point represents a 1-point change at 4 weeks1

image description

Careers with Revance

Do you have what it takes to join our team? Check out our Careers page and find out.

Learn More

References

  1. Revance Data on File

Disclaimers

* DAXI is an investigational agent that is not approved by the FDA, nor has the FDA determined it to be safe or efficacious in humans. Anticipated approval in 2020.

Back to top